Advertisement

Springer Seminars in Immunopathology

, Volume 27, Issue 1, pp 37–48 | Cite as

CD4 T cells in tumor immunity

  • Mara Gerloni
  • Maurizio Zanetti
Original Article

Abstract

T cell immunity is the key to protective immune responses against tumors. Traditionally, this function has been ascribed to CD8 T lymphocytes with cytotoxic activity, which are restricted by MHC class I molecules. In recent years the realization that CD4 T cells can also play a relevant role in protective anti-tumor responses has received growing attention. Here we will discuss the role of MHC class II-restricted T cells in response to, and in the regulation of, tumor antigens. Emphasis will be placed on four areas: (1) the role of CD4 T cell immunity in tumor protection in animal models and putative mode of action, (2) tumor antigens recognized by human CD4 T cells, (3) the cooperation between two CD4 T cells of different specificity as a new way to jump start the response against sub-immunogenic determinants of tumor antigens in a tolerant environment, and (4) the negative impact of regulatory CD4 T cells on anti-tumor T cell responses. By drawing attention to these four areas, it is our intention to provide the reader with a comprehensive view of issues of contemporary importance for this field, in the expectation that the information will help a better design of therapeutic cancer vaccines.

Keywords

Tumor immunity CD4 T cells MHC class II Th-Th cell cooperation 

Notes

Acknowledgements

This work was supported by NIH grant RO1CA77427 and a pilot grant from the Medicine Education Research Foundation.

References

  1. 1.
    Burnet FM (1971) Immunological surveillance in neoplasia. Transplant Rev 7:3Google Scholar
  2. 2.
    Rammensee HG, Friede T, Stevanoviic S (1995) MHC ligands and peptide motifs: first listing. Immunogenetics 41:178Google Scholar
  3. 3.
    O’Garra A, Murphy K (1994) Role of cytokines in determining T-lymphocyte function. Curr Opin Immunol 6:458Google Scholar
  4. 4.
    Waldmann TA (2003) Immunotherapy: past, present and future. Nat Med 9:269Google Scholar
  5. 5.
    Kappler JW, Roehm N, Marrack P (1987) T cell tolerance by clonal elimination in the thymus. Cell 49:273Google Scholar
  6. 6.
    Cobbold SP, Adams E, Marshall SE, et al (1996) Mechanisms of peripheral tolerance and suppression induced by monoclonal antibodies to CD4 and CD8. Immunol Rev 149:5Google Scholar
  7. 7.
    Ochsenbein AF, Klenerman P, Karrer U, et al (1999) Immune surveillance against a solid tumor fails because of immunological ignorance. Proc Natl Acad Sci USA 96:2233Google Scholar
  8. 8.
    Sercarz EE, Lehmann PV, Ametani A, et al (1993) Dominance and crypticity of T cell antigenic determinants. Annu Rev Immunol 11:729Google Scholar
  9. 9.
    Mitchison NA (1971) The carrier effect in the secondary response to hapten-protein conjugates. II. Cellular cooperation. Eur J Immunol 1:18Google Scholar
  10. 10.
    Keene JA, Forman J (1982) Helper activity is required for the in vivo generation of cytotoxic T lymphocytes. J Exp Med 155:768Google Scholar
  11. 11.
    Swain SL, Bradley LM, Croft M, et al (1991) Helper T-cell subsets: phenotype, function and the role of lymphokines in regulating their development. Immunol Rev 123:115Google Scholar
  12. 12.
    Carter LL, Dutton RW (1996) Type 1 and type 2: a fundamental dichotomy for all T-cell subsets. Curr Opin Immunol 8:336Google Scholar
  13. 13.
    Janssen EM, Lemmens EE, Wolfe T, et al (2003) CD4+ T cells are required for secondary expansion and memory in CD8+ T lymphocytes. Nature 421:852Google Scholar
  14. 14.
    Shedlock DJ, Shen H (2003) Requirement for CD4 T cell help in generating functional CD8 T cell memory. Science 300:337Google Scholar
  15. 15.
    Sun JC, Bevan MJ (2003) Defective CD8 T cell memory following acute infection without CD4 T cell help. Science 300:339Google Scholar
  16. 16.
    Sun JC, Williams MA, Bevan MJ (2004) CD4+ T cells are required for the maintenance, not programming, of memory CD8+ T cells after acute infection. Nat Immunol 5:927Google Scholar
  17. 17.
    Langlade-Demoyen P, Garcia-Pons F, Castiglioni P, et al (2003) Role of T cell help and endoplasmic reticulum targeting in protective CTL response against influenza virus. Eur J Immunol 33:720Google Scholar
  18. 18.
    Ossendorp F, Mengede E, Camps M, et al (1998) Specific T helper cell requirement for optimal induction of cytotoxic T lymphocytes against major histocompatibility complex class II negative tumors. J Exp Med 187:693Google Scholar
  19. 19.
    Greenberg PD, Cheever MA, Fefer A (1981) Eradication of disseminated murine leukemia by chemoimmunotherapy with cyclophosphamide and adoptively transferred immune syngeneic Lyt-1+2 lymphocytes. J Exp Med 154:952Google Scholar
  20. 20.
    Fujiwara H, Fukuzawa M, Yoshioka T, et al (1984) The role of tumor-specific Lyt-1+2 T cells in eradicating tumor cells in vivo. I. Lyt-1+2 T cells do not necessarily require recruitment of host’s cytotoxic T cell precursors for implementation of in vivo immunity. J Immunol 133:1671Google Scholar
  21. 21.
    Hock H, Dorsch M, Diamantstein T, et al (1991) Interleukin 7 induces CD4+ T cell-dependent tumor rejection. J Exp Med 174:1291Google Scholar
  22. 22.
    Lauritzsen GF, Weiss S, Dembic Z, et al (1994) Naive idiotype-specific CD4+ T cells and immunosurveillance of B-cell tumors. Proc Natl Acad Sci USA 91:5700Google Scholar
  23. 23.
    Hung K, Hayashi R, Lafond-Walker A, et al (1998) The central role of CD4(+) T cells in the antitumor immune response. J Exp Med 188:2357Google Scholar
  24. 24.
    Heath WR, Carbone FR (1999) Cytotoxic T lymphocyte activation by cross-priming. Curr Opin Immunol 11:314Google Scholar
  25. 25.
    Pieper R, Christian RE, Gonzales MI, et al (1999) Biochemical identification of a mutated human melanoma antigen recognized by CD4(+) T cells. J Exp Med 189:757Google Scholar
  26. 26.
    Wang RF, Wang X, Rosenberg SA (1999) Identification of a novel major histocompatibility complex class II-restricted tumor antigen resulting from a chromosomal rearrangement recognized by CD4(+) T cells. J Exp Med 189:1659Google Scholar
  27. 27.
    Wang RF, Wang X, Atwood AC, et al (1999) Cloning genes encoding MHC class II-restricted antigens: mutated CDC27 as a tumor antigen. Science 284:1351Google Scholar
  28. 28.
    Greenberg PD (1991) Adoptive T cell therapy of tumors: mechanisms operative in the recognition and elimination of tumor cells. Adv Immunol 49:281Google Scholar
  29. 29.
    Dighe AS, Richards E, Old LJ, et al (1994) Enhanced in vivo growth and resistance to rejection of tumor cells expressing dominant negative IFN gamma receptors. Immunity 1:447Google Scholar
  30. 30.
    Williamson BD, Carswell EA, Rubin BY, et al (1983) Human tumor necrosis factor produced by human B-cell lines: synergistic cytotoxic interaction with human interferon. Proc Natl Acad Sci USA 80:5397Google Scholar
  31. 31.
    Fransen L, Van der Heyden J, Ruysschaert R, et al (1986) Recombinant tumor necrosis factor: its effect and its synergism with interferon-gamma on a variety of normal and transformed human cell lines. Eur J Cancer Clin Oncol 22:419Google Scholar
  32. 32.
    Coughlin CM, Salhany KE, Gee MS, et al (1998) Tumor cell responses to IFNgamma affect tumorigenicity and response to IL-12 therapy and antiangiogenesis. Immunity 9:25Google Scholar
  33. 33.
    Qin Z, Blankenstein T (2000) CD4+ T cell-mediated tumor rejection involves inhibition of angiogenesis that is dependent on IFN gamma receptor expression by nonhematopoietic cells. Immunity 12:677Google Scholar
  34. 34.
    Gerloni M, Xiong S, Mukerjee S, et al (2000) Functional cooperation between Th cell determinants. Proc Natl Acad Sci USA 97:13269Google Scholar
  35. 35.
    Hilkens J, Buijs F, Hilgers J, et al (1984) Monoclonal antibodies against human milk-fat globule membranes detecting differentiation antigens of the mammary gland and its tumors. Int J Cancer 34:197Google Scholar
  36. 36.
    Lloyd KO, Burchell J, Kudryashov V, et al (1996) Comparison of O-linked carbohydrate chains in MUC-1 mucin from normal breast epithelial cell lines and breast carcinoma cell lines. Demonstration of simpler and fewer glycan chains in tumor cells. J Biol Chem 271:33325Google Scholar
  37. 37.
    Gerloni M, Miner KT, Xiong S, et al (1999) Activation of CD4 T cells by somatic transgenesis induces generalized immunity of uncommitted T cells and immunologic memory. J Immunol 162:3782Google Scholar
  38. 38.
    Pecher G, Finn OJ (1996) Induction of cellular immunity in chimpanzees to human tumor-associated antigen mucin by vaccination with MUC-1 cDNA-transfected Epstein-Barr virus-immortalized autologous B cells. Proc Natl Acad Sci USA 93:1699Google Scholar
  39. 39.
    Gong J, Chen D, Kashiwaba M, et al (1998) Reversal of tolerance to human MUC1 antigen in MUC1 transgenic mice immunized with fusions of dendritic and carcinoma cells. Proc Natl Acad Sci USA 95:6279Google Scholar
  40. 40.
    Soares MM, Mehta V, Finn OJ (2001) Three different vaccines based on the 140-amino acid MUC1 peptide with seven tandemly repeated tumor-specific epitopes elicit distinct immune effector mechanisms in wild-type versus MUC1-transgenic mice with different potential for tumor rejection. J Immunol 166:6555Google Scholar
  41. 41.
    Tempero RM, VanLith ML, Morikane K, et al (1998) CD4+ lymphocytes provide MUC1-specific tumor immunity in vivo that is undetectable in vitro and is absent in MUC1 transgenic mice. J Immunol 161:5500Google Scholar
  42. 42.
    Bretscher P, Cohn M (1970) A theory of self-nonself discrimination. Science 169:1042Google Scholar
  43. 43.
    Gershon RK (1975) A disquisition on suppressor T cells. Transplant Rev 26:170Google Scholar
  44. 44.
    Shevach EM, McHugh RS, Piccirillo CA, et al (2001) Control of T-cell activation by CD4+ CD25+ suppressor T cells. Immunol Rev 182:58Google Scholar
  45. 45.
    Roncarolo MG, Bacchetta R, Bordignon C, et al (2001) Type 1 T regulatory cells. Immunol Rev 182:68Google Scholar
  46. 46.
    Misra N, Bayry J, Lacroix-Desmazes S, et al (2004) Cutting edge: Human CD4+CD25+ T cells restrain the maturation and antigen-presenting function of dendritic cells. J Immunol 172:4676Google Scholar
  47. 47.
    Cantor H (2004) Reviving suppression? Nat Immunol 5:347Google Scholar
  48. 48.
    Jiang H, Zhang SI, Pernis B (1992) Role of CD8+ T cells in murine experimental allergic encephalomyelitis. Science 256:1213Google Scholar
  49. 49.
    North RJ (1982) Cyclophosphamide-facilitated adoptive immunotherapy of an established tumor depends on elimination of tumor-induced suppressor T cells. J Exp Med 155:1063Google Scholar
  50. 50.
    Shimizu J, Yamazaki S, Sakaguchi S (1999) Induction of tumor immunity by removing CD25+CD4+ T cells: a common basis between tumor immunity and autoimmunity. J Immunol 163:5211Google Scholar
  51. 51.
    Onizuka S, Tawara I, Shimizu J, et al (1999) Tumor rejection by in vivo administration of anti-CD25 (interleukin-2 receptor alpha) monoclonal antibody. Cancer Res 59:3128Google Scholar
  52. 52.
    Daniels GA, Sanchez-Perez L, Diaz RM, et al (2004) A simple method to cure established tumors by inflammatory killing of normal cells. Nat Biotechnol 22:1125Google Scholar
  53. 53.
    Sutmuller RP, Duivenvoorde LM van, Elsas A van, et al (2001) Synergism of cytotoxic T lymphocyte-associated antigen 4 blockade and depletion of CD25(+) regulatory T cells in antitumor therapy reveals alternative pathways for suppression of autoreactive cytotoxic T lymphocyte responses. J Exp Med 194:823Google Scholar
  54. 54.
    Ghiringhelli F, Larmonier N, Schmitt E, et al (2004) CD4+CD25+ regulatory T cells suppress tumor immunity but are sensitive to cyclophosphamide which allows immunotherapy of established tumors to be curative. Eur J Immunol 34:336Google Scholar
  55. 55.
    Sakaguchi S (2003) Control of immune responses by naturally arising CD4+ regulatory T cells that express toll-like receptors. J Exp Med 197:397Google Scholar
  56. 56.
    Javia LR, Rosenberg SA (2003) CD4+CD25+ suppressor lymphocytes in the circulation of patients immunized against melanoma antigens. J Immunother 26:85Google Scholar
  57. 57.
    Viguier M, Lemaitre F, Verola O, et al (2004) Foxp3 expressing CD4+CD25high regulatory T cells are overrepresented in human metastatic melanoma lymph nodes and inhibit the function of infiltrating T cells. J Immunol 173:1444Google Scholar
  58. 58.
    Curiel TJ, Coukos G, Zou L, et al (2004) Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival. Nat Med 10:942Google Scholar
  59. 59.
    Padua RA, Larghero J, Robin M, et al (2003) PML-RARA-targeted DNA vaccine induces protective immunity in a mouse model of leukemia. Nat Med 9:1413Google Scholar
  60. 60.
    Lehmann PV, Forsthuber T, Miller A, et al (1992) Spreading of T-cell autoimmunity to cryptic determinants of an autoantigen. Nature 358:155Google Scholar
  61. 61.
    Wang HY, Lee DA, Peng G, et al (2004) Tumor-specific human CD4+ regulatory T cells and their ligands: implications for immunotherapy. Immunity 20:107Google Scholar
  62. 62.
    Kobayashi H, Kokubo T, Sato K, et al (1998) CD4+ T cells from peripheral blood of a melanoma patient recognize peptides derived from nonmutated tyrosinase. Cancer Res 58:296Google Scholar
  63. 63.
    Kobayashi H, Kokubo T, Takahashi M, et al (1998) Tyrosinase epitope recognized by an HLA-DR-restricted T-cell line from a Vogt-Koyanagi-Harada disease patient. Immunogenetics 47:398Google Scholar
  64. 64.
    Touloukian CE, Leitner WW, Schnur RE, et al (2003) Normal tissue depresses while tumor tissue enhances human T cell responses in vivo to a novel self/tumor melanoma antigen, OA1. J Immunol 170:1579Google Scholar
  65. 65.
    Zarour HM, Kirkwood JM, Kierstead LS, et al (2000) Melan-A/MART-1(51–73) represents an immunogenic HLA-DR4-restricted epitope recognized by melanoma-reactive CD4(+) T cells. Proc Natl Acad Sci USA 97:400Google Scholar
  66. 66.
    Li K, Adibzadeh M, Halder T, et al (1998) Tumour-specific MHC-class-II-restricted responses after in vitro sensitization to synthetic peptides corresponding to gp100 and Annexin II eluted from melanoma cells. Cancer Immunol Immunother 47:32Google Scholar
  67. 67.
    Touloukian CE, Leitner WW, Topalian SL, et al (2000) Identification of a MHC class II-restricted human gp100 epitope using DR4-IE transgenic mice. J Immunol 164:3535Google Scholar
  68. 68.
    Chaux P, Vantomme V, Stroobant V, et al (1999) Identification of MAGE-3 epitopes presented by HLA-DR molecules to CD4(+) T lymphocytes. J Exp Med 189:767Google Scholar
  69. 69.
    Manici S, Sturniolo T, Imro MA, et al (1999) Melanoma cells present a MAGE-3 epitope to CD4(+) cytotoxic T cells in association with histocompatibility leukocyte antigen DR11. J Exp Med 189:871Google Scholar
  70. 70.
    Campi G, Crosti M, Consogno G, et al (2003) CD4(+) T cells from healthy subjects and colon cancer patients recognize a carcinoembryonic antigen-specific immunodominant epitope. Cancer Res 63:8481Google Scholar
  71. 71.
    Zeng G, Touloukian CE, Wang X, et al (2000) Identification of CD4+ T cell epitopes from NY-ESO-1 presented by HLA-DR molecules. J Immunol 165:1153Google Scholar
  72. 72.
    Zarour HM, Storkus WJ, Brusic V, et al (2000) NY-ESO-1 encodes DRB1*0401-restricted epitopes recognized by melanoma-reactive CD4+ T cells. Cancer Res 60:4946Google Scholar
  73. 73.
    Zeng G, Wang X, Robbins PF, et al (2001) CD4(+) T cell recognition of MHC class II-restricted epitopes from NY-ESO-1 presented by a prevalent HLA DP4 allele: association with NY-ESO-1 antibody production. Proc Natl Acad Sci USA 98:3964Google Scholar
  74. 74.
    Slager EH, Minne CE van der, Kruse M, et al (2004) Identification of multiple HLA-DR-restricted epitopes of the tumor-associated antigen CAMEL by CD4+ Th1/Th2 lymphocytes. J Immunol 172:5095Google Scholar
  75. 75.
    Maccalli C, Li YF, El-Gamil M, et al (2003) Identification of a colorectal tumor-associated antigen (COA-1) recognized by CD4(+) T lymphocytes. Cancer Res 63:6735Google Scholar
  76. 76.
    Mandic M, Almunia C, Vicel S, et al (2003) The alternative open reading frame of LAGE-1 gives rise to multiple promiscuous HLA-DR-restricted epitopes recognized by T-helper 1-type tumor-reactive CD4+ T cells. Cancer Res 63:6506Google Scholar
  77. 77.
    Disis ML, Schiffman K, Gooley TA, et al (2000) Delayed-type hypersensitivity response is a predictor of peripheral blood T-cell immunity after HER-2/neu peptide immunization. Clin Cancer Res 6:1347Google Scholar
  78. 78.
    Chikamatsu K, Albers A, Stanson J, et al (2003) P53(110)-specific human CD4+ T-helper cells enhance in vitro generation and antitumor function of tumor-reactive CD8+ T cells. Cancer Res 63:3675Google Scholar
  79. 79.
    Hiltbold EM, Ciborowski P, Finn OJ (1998) Naturally processed class II epitope from the tumor antigen MUC1 primes human CD4+ T cells. Cancer Res 58:5066Google Scholar
  80. 80.
    Schroers R, Shen L, Rollins L, et al (2003) Human telomerase reverse transcriptase-specific T-helper responses induced by promiscuous major histocompatibility complex class II-restricted epitopes. Clin Cancer Res 9:4743Google Scholar
  81. 81.
    Jong A de, Poelgeest MI van, Hulst JM van der, et al (2004) Human papillomavirus type 16-positive cervical cancer is associated with impaired CD4+ T-cell immunity against early antigens E2 and E6. Cancer Res 64:5449Google Scholar
  82. 82.
    Kruger S, Schroers R, Rooney CM, et al (2003) Identification of a naturally processed HLA-DR-restricted T-helper epitope in Epstein-Barr virus nuclear antigen type 1. J Immunother 26:212Google Scholar

Copyright information

© Springer-Verlag 2005

Authors and Affiliations

  1. 1.The Laboratory of Immunology, Department of Medicine and Cancer CenterUniversity of California, San DiegoLa JollaUSA

Personalised recommendations